<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654082</url>
  </required_header>
  <id_info>
    <org_study_id>A1481103</org_study_id>
    <nct_id>NCT00654082</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction</brief_title>
  <official_title>A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy, safety and tolerability of sildenafil administered orally, as
      required, approximately 1 hour prior to sexual activity to men with erectile dysfunction (ED)
      associated with spinal cord injury (SCI), as well as its effects on the quality of life (QoL)
      of these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who indicated a preference for either treatment and who said that the treatment improved their erections</measure>
    <time_frame>Weeks 6 and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responses to the International Index of Erectile Function (IIEF)</measure>
    <time_frame>Weeks 0, 6, 8, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to the Global Efficacy Assessment (GEA) Question</measure>
    <time_frame>Weeks 0, 6, 8, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to questions on the Quality of Life (QoL) Questionnaire</measure>
    <time_frame>Weeks 0, 6, 8, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questions</measure>
    <time_frame>Weeks 0, 6, 8, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intercourse success rate derived from patient event log</measure>
    <time_frame>Weeks 0, 6, 8, and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Erectile Dysfunction</condition>
  <condition>Spinal Cord Trauma</condition>
  <condition>Injuries, Spinal Cord</condition>
  <condition>Impotence</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients were men with spinal cord injury and erectile dysfunction

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bahcelievler</city>
        <state>Istanbul</state>
        <zip>34580</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Balcova</city>
        <state>Izmir</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481103&amp;StudyName=A%20Study%20Evaluating%20the%20Efficacy%20and%20Safety%20of%20Sildenafil%20in%20Men%20with%20Traumatic%20Spinal%20Cord%20Injury%20and%20Erectile%20Dysfunction.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>April 2, 2008</last_update_submitted>
  <last_update_submitted_qc>April 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Spinal Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

